In univariate analysis, patients with EGFR-mutant NSCLC were also more likely to respond to treatment than those with EGFR-WT NSCLC (ORR = 24.0, 95% CI = 2.4–240.6, P = 0.0007), whereas the small size of the EGFR-WT cohort precluded multivariate analysis. Here, EGFR is linked to non-small cell lung carcinoma.